Publications & Presentations * Publications * Clinical * 2000-2005
Clinical Publications 2000-2005

1 Death in the era of potent antiretroviral therapy: shifting causes, new challenges. M Zwahlen and JD Lundgren
Int J Epidemiol. 2005 Jan 13. abstract

2 Risk of AIDS and death at given HIV-RNA and CD4 count levels, according to specific antiretroviral drugs in the regimen. Holkmann Olsen C, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren J, Phillips A.
AIDS. 2005 Feb 18; 19:319-330 abstract

3 Prospective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis-Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis. Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K.
Clin Diagn Lab Immunol. 2005 Apr, 12(4):491-6 abstract

4 Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. D Konopnicki, A Mocroft, S De Wit, F Antunes, B Ledergerber, C Katlama, K Zilmer, S Vella, O Kirk, and JD Lundgren for the EuroSIDA Group.
AIDS. 2005 Apr 8;19(6):593-601 abstract

5 Short statement of the first European Consensus Conference o­n the treatment of chronic hepatitis B and C in HIV co-infected patients. A Alberti, N Clumeck, S Collins, W Gerlich, J Lundgren, G Palù, P Reiss, R Thiebaut, O Weiland, Y Yazdanpanah, S Zeuzem (The ECC Jury).
J Hepatol. 2005 May;42(5):615-24 abstract

6 Decline in oesophageal candidiasis and use of antimycotics in patients with HIV. A Mocroft, C Oancea, J van Lunzen, P Vanhems, D Banhegyi, A Chiesi, E Vinogradova, S Maayan, AN Phillips and J Lundgren.  Am J Gastroenterol. 2005 Jul;100(7):1446-54. abstract

7 Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal menigitis. CT Brandt, JD Lundgren, N Frimodt-Møller, T Christensen, T Benfield, F Espersen, DM Hougaard, C Østergaard.
J Neuroimmunol. 2005 Sep;166(1-2):126-31 abstract

8 Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection. A Mocroft, AN. Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren  AIDS Res Hum Retroviruses. Sep 2005, Vol. 21, No. 9: 743-752 abstract

9 Impact of Coinfection With HIV-1 and GB Virus C in Patients Receiving a Ritonavir-Boosted HAART Regimen: A Substudy to the MaxCmin1 Trial. HL Tillmann, T Kaiser, Z Fox, S Staszewski, F Antunes, AD Monforte, P Vernazza, A Hill, UB Dragsted, JD Lundgren; o­n behalf of the MaxCmin1 Trial Group. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):378-380 abstract

10 Genetic evolution of HIV in patients remaining o­n a stable HAART regimen despite insufficient viral suppression. TB Kristiansen, AG Pedersen, J Eugen-Olsen, TL Katzenstein and JD Lundgren. Scand J Infect Dis 2005; 37:890-901 abstract

11 Influence of Hepatitis C o­n HIV Disease Progression and Response to Antiretroviral Therapy. J Rockstroh, A Mocroft, V Soriano, C Tural, M Losso, A Horban, O Kirk, A Phillips, B Ledergerber, J Lundgren for the EuroSIDA study group. J Infect Dis. 2005 Sep 15;192(6):992-1002 abstract

12 Is there evidence for an increase in the death-rate from liver-related disease in patients with HIV? A Mocroft, V Soriano, J Rockstroh, P Reiss, O Kirk, S de Wit, J Gatell, B Clotet, AN Phillips, JD Lundgren for the EuroSIDA study group. AIDS. 2005 Dec 2; 19(18):2117-2125 abstract

13 Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. A Mocroft, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, AN Phillips, JD Lundgren for the EuroSIDA study group. Antivir. Ther. 2005;10(7):779-90 abstract

14 Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact o­n the virological response to therapy. A Cozzi-Lepri, L Ruiz, C Loveday, AN Phillips, B Clotet, P Reiss, B Ledergerber, C Holkman Olsen, S Staszewski and JD Lundgren for the EuroSIDA Study Group.  Antivir Ther. 2005;10(7):791-802. abstract

15 Predictors of hypertension and changes of blood pressure in HIV-infected patients. R Thiebaut, WM El-Sadr, N Friis-Moller, M Rickenbach, P Reiss, AD Monforte, L Morfeldt, E Fontas, O Kirk, S De Wit, G Calvo, MG Law, F Dabis, CA Sabin, JD Lundgren; Data Collection of Adverse events of anti-HIV Drugs Study Group. Antivir Ther. 2005;10(7):811-23 abstract

16 Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. E Girardi, CA Sabin, A d'Arminio Monforte, B Hogg, AN Phillips, MJ Gill, F Dabis, P Reiss, O Kirk, E Bernasconi, S Grabar, A Justice, S Staszewski, G Fatkenheuer, JA Sterne; Antiretroviral Therapy Cohort Collaboration. Clin Infect Dis. 2005 Dec 15;41(12):1772-82. abstract

17 A randomised trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected subjects. The MaxCmin2 trial. UB Dragsted, J Gerstoft, M Youle, Z Fox, M Losso, J Benetucci, DT Jayawwera, A Rieger, JN Bruun, A Castagna, B Gazzard, S Walmsley, A Hill, and JD Lundgren for the MaxCmin2 trial group. Antivir Ther. 2005;10(6):735-43. abstract

18 The ART Cohort Collaboration: AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? Writing committee: Sabin, CA, Hogg B, Dabis F, Gill MJ, Phillips AN, Reiss P, Fätkenheuer G, Grabar S, Lundgren J, Justice A, Ledergerber B, d'Arminio Monforte A, Staszewski A and Sterne JAC. AIDS 2005 19: 1995-2000. abstract

19 Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. Margaret May, Kholoud Porter, Jonathan A. C. Sterne, Patrick Royston, Matthias Egger, ART-CC (The Antiretroviral Therapy Cohort Collaboration) and CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe). Journal of Clinical Epidemiology 2005 58: 1033-1041. abstract 

20 The ART Cohort Collaboration: The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Writing committee: D'Arminio MA, Sabin CA, Phillips A, Sterne JAC, May M, Justice AC, Dabis F, Grabar C, Ledergerber B, Gill J, Reiss P and Egger M. Archives of Internal Medicine 2005 165: 416-23 abstract


1 Changing incidence of CNS HIV-related diseases in the EuroSIDA cohort. d´Arminio Monforte A, Cinque P, Mocroft A, Goebel F-D, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren JD, for the EuroSIDA Study Group. Ann Neurol. 2004; 55:320-328 abstract

2 Lipid profiles in HIV-1-infected individuals receiving combination antiretroviral therapy: are different protease inhibitors or non-nucleoside reverse transcriptase inhibitors associated with different lipid profiles? Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d’Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P.
J Infect Dis. 2004;189 abstract

3 Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Ostergaard C, Benfield T, Lundgren JD and Eugen-Olsen J. Scand J Infect Dis. 2004;36:14-19abstract

4 Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicines. Kirk O and Lundgren JD. Cur Opin Infect Dis. 2004;17:33-37 abstract

5 Indirect comparisons: a novel approach to assessing the effect of anti-HIV drugs. Lundgren JD, Phillips AN. BMJ. 2004;328(7434):253 abstract

6 The PLATO Collaboration. Predictors of CD4 count trend and mortality among HIV-1 - infected patients with virologic failure to all three antiretroviral drug classes. Writing committee: Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe, F Gill J, Castelli F, Phillips AN.
Lancet. 2004;364:51-62 abstract

7 HIV survival benefit associated with earlier antiviral therapy. Mocroft A, Phillips AN, Lundgren JD. Ann Inter Med. 2004;140(7):578-9 abstract

8 Forscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. Mathiesen S, Roge BT, Weis N, Lundgren JD, Obel N, Gerstoft J. AIDS 2004;18(7):1076-78 abstract

9 The Changing pattern of Kaposi´s sarcoma in patients with HIV - 1994-2003. The EuroSIDA Study. Mocroft A, Kirk O, Clumeck N, Gargalianos P, Trocha H, Chentsova N, Antunes F, Stellbrink H-J, Phillips AN, Lundgren JD for the EuroSIDA study group. Cancer 2004; 100:2644-2654 abstract

10 Predictors of immunological failure after initial response to HAART in HIV-1 infected adults: a EuroSIDA study. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AE, Panos G, Mercey D, Machala L, Horban A, and Lundgren JD; EuroSIDA study group.
J Infect Dis. 2004 Jul 1;190(1):148-55 abstract

11 Reduktion af aids og dødsrater i EuroSIDA-studiet. Et observationsstudie. Kirk O, Mocroft A and Lundgren JD for the EuroSIDA study.
Ugeskrift Laeger. 2004;166(26-31):2571-6 abstract

12 HIV cohort collaborations: proposal for harmonization of data exchange. Kjaer J and Ledergerber B. Antivir. Ther. 2004;9:631-3 abstract

13 Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. Collaboration of HIV Cohorts, writing committee: Phillips AN, Ledergerber B, Lundgren JD, Hogg B, d'Arminio Monforte A, Castelli F, Walker S, Staszewski S, Thiébaut R, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D. J Infect Dis 2004;190:675-87 abstract

14 Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe. A EuroSIDA study, 1994-2000. Yust I, Fox Z, Burke M, Johnson AM, Tuner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O, for the EuroSIDA study. Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):550-9 abstract

15 Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group. AIDS. 2004 Sep 3;18(13):1795-804 abstract

16 Cardio- and Cerebrovascular Events in HIV-Infected Persons. The Data Collection o­n Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.Writing Committee: d'Arminio Monforte A, Sabin CA, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Phillips AN, Lundgren JD, and Friis-Moller N. AIDS 2004, 18:1811-1817 abstract

17 HIV remains a deadly disease. Lundgren JD HIV med. 2004;5:251-2 abstract

18 Attenuation of the blood bacterial load by pre-treatment with G-CSF protects from fatal outcome and brain damage in Streptococcus pneumoniae meningitis in rats. Brandt CT, Lundgren JD, Lund SP, Frimodt-Møller N, Christensen T, Benfield T, Espersen F, Hougaard DM and Østergaard C. Infect Immun. 2004 Aug;72(8):4647-53 abstract

19 Starting antiretroviral therapy: why, when and response to HAART [review]. Mocroft A, Lundgren JD J Antimicrob Chemother. 2004 Jul;54(1):10-3. Epub 2004 May 26. Review abstract

20 Is the Salk principle still viable for the design of an effective HIV vaccine? [editorial]. Lundgren JD HIV Med. 2004 Sep;5(5):315-6 abstract

21 Current Epidemiology of Pneumocystis Pneumonia. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson D, Frederick T, Huang L, Beard C and Kaplan JE Emerg Infect Dis. 2004 Oct;10(10):1713-20. abstract

22 Baseline Resistance and Virologic Outcome in Patients with Virologic Failure who start a Regimen Containing Abacavir: EuroSIDA Study. Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjær J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L o­n behalf of the EuroSIDA study group.  Antivir Ther. 2004 Oct;9(5):787-800. abstract

23 Changes in hospital admissions across Europe:1994-2003. Results from the EuroSIDA study. Mocroft A, d’Arminio Monforte A, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, Blaxhult A, Mulcahy F, Gatell JM, Lundgren JD for the EuroSIDA study group. HIV Med. 2004 Nov;5(6):437-47. abstract

24 A prospective, blinded study of quantitative touch-down PCR using oral washes for diagnosis of Pneumocystis Pneumonia in patients with HIV infection. Larsen HH, Huang L, Kovacs JA, Crothers K, Silcott VA, Morris A, Turner JR, Beard CB, Masur H, and Fischer SH.
J Infect Dis. 2004 May 1;189(9):1679-83. Epub 2004 Apr 16 abstract

25 Time to virological failure of three classes of antiretrovirals after initiation of HAART : Results from the EuroSIDA study group. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen A-B E, Phillips AN, Lundgren JD for the EuroSIDA study group
J Infect Dis. 2004 Dec 1;190(11):1947-56. Epub 2004 Oct 28. abstract

26 Causes of death in HIV infection:the key determinant to define the clinical response to anti-HIV therapy. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J; for the EuroSIDA study group. AIDS. 2004 Nov 19;18(17):2333-2337 abstract

27 Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. Roge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J. HIV med. 2004 Sep;5(5):344-51 abstract

28 Updated European recommendations for the clinical use of HIV drug resistance testing. Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmitt JC, Schuurmann R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R and Perrin L.  Antivir Ther. 2004 9:829-848 abstract

29 Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. May M, Royston P, Egger M, Justice AC, Sterne JAC and the ART Cohort Collaboration. Statistics in Medicine 2004 23: 2375-98. abstract


1 Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D´Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, and Gatell JM for the BEST study team. AIDS. 2003,17:831-840.abstract

2 An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Writing Committee: Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG, for the HIV Lipodystrophy Case Definition Study Group. Lancet. 2003;361(9359):726-35. abstract

3 S-adenosylmethionine in plasma to test for Pneumoscystis carinii pneumonia.  Helweg-Larsen J. Lancet. 2003 ;361(9365):1237. abstract

4 Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lundgren JD, Phillips AN for the EuroSIDA group. J Acquir Immune Defic Syndr 2003 ;32(4):452-61 abstract

5 Modelling the three year risk of myocardial infarction among participants in the D:A:D study. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD, for the DAD Study Group.
HIV Med. 2003; 4(1):1-10. abstract

6 Cardiovascular risk factors in HIV patients - association with antiretroviral therapy Results from the DAD Study. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, for the DAD study group AIDS. 2003; 17(8):1179-1193 abstract

7 Changes in viral load in people with virological failure who remain o­n the Same HAART regimen. Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgren JD.  Antivir Ther. 2003 ;8(2):127-36 abstract

8 Decline in the AIDS and death rates in the EuroSIDA study: an observational study.  Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD, for the EuroSIDA study group. Lancet. 2003; 362: 22–29. abstract

9 Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A; The EuroSIDA Study Group.  HIV Med. 2003 Jul;4(3):255-262. abstract

10 K65R with and withourt S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Røge BT, Katzenstein TL, Obel N, Pedersen C, Mathiesen L, Lundgren JD and Gerstoft J.  Antivir Ther. 2003; 8:173-182 abstract

11 Randomised trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in HIV-1 infected patients: The MaxCmin1 Trial. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD for the MaxCmin1 trial group. J Infect Dis. 2003;188:635-642 abstract

12 Virological rebound after suppression o­n highly active antiretroviral therapy. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel F-D, Phillips AN, Clotet B, Lundgren JD, for the EuroSIDA study group.  AIDS. 2003 ;17(12):1741-1751 abstract

13 Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Writing Committee: Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME, for the Antiretroviral Therapy Cohort Collaboration.
Lancet. 2003 ;362(9385):679-86 abstract

14 Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The Data Collection o­n Adverse Events of Anti-HIV Drugs for the D:A:D Study Group.  Writing Committee: Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD, for the DAD Study group. N Engl J Med. 2003; 349(21);1993-2003. abstract

15 Monitoring of long-term toxicities of HIV treatments: an international perspective. Bisson G, Gross R, Miller V, Weller I, Walker A, o­n behalf of the wrinting group: Arlett P, Carr A, Evans S, Graham D, Justice A, Kreft-Jais C, Lundgren JD, Munk B, Murray J, Pirmohamed M, Pizzuti D, Szarfman A. AIDS. 2003;17:2407-2417 abstract

16 Dyslipidaemia and cardiovascular disease risk associated with antiretroviral drugs. Lundgren JD. Pharmacoepidemiol Drug Saf. 2003; 12:357-359 abstract

17 Anemia and Survival in Human Immunodeficiency Virus. Lundgren JD and Mocroft A. Clin Infect Dis. 2003;37(Suppl. 4):S297-303 abstract

18 Low efficacy and high frequency of adverse event in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD. AIDS. 2003; 17(14):2045-2022 abstract

19 A randomized trial comparing initial HAART regimens for nelfinavir/nevirapine and ritonavir/saquinavir in combinatin with two nucleoside reverse transcriptase inhibitors. Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
Antivir Ther. 2003; 8(6):595-602 abstract


1 The Evaluation of Subcutaneous Proleukin((R)) (interleukin-2) in a Randomized International Trial. Rationale, design, and methods of ESPRIT.
Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD and the ESPRIT Study Group Control Clin Trials. 2002;23(2):198-220. abstract

2 No evidence of parvovirus B19, Chlamydia pneumoniae orhuman herpes virus infection in temporal artery biopsies in patients with giantcell arteritis. Helweg-Larsen J, Tarp B, Obel N, and Baslund B  Rheumatology(Oxford).2002;41(4):445-449. abstract

3 A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O, and Phillips A N for the EuroSIDA Study Group J Infect Dis.2002;185(2):178-187. abstract

4 Regulatory approvals in a large multinational clinical trial. The ESPRIT experience. McNay LA, Tavel JA., Oseekey K, McDermott CM, Mollerup D, Bebchuk JD for the ESPRIT Group. Control Clin Trials. 2002;23(1):59-66.abstract

5 The naive CD4+ count in HIV-1-infected patients at time of initiation of highly active antiretroviral therapy is strongly associated with the level of immunological recovery. Michael CG, Kirk O, Mathiesen L, and Nielsen SD Scand J Infect Dis.2002;34(1):45-49. abstract

6 Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: Results from the EuroSIDA study. Mocroft A, Phillips AN,Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B, Lundgren JD for the EuroSIDA study group.
Antivir Ther. 2002; 7:21-30. abstract

7 Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cellcounts: The EuroSIDA study. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormassen V, Gargalianos-Kakolyris P, Vella S and Lundgren JD for the EuroSIDA Study Group J Infect Dis 2002;186:189-197 abstract

8 Changes in the cause of death among HIV positive subjects across Europe: Results from the EuroSIDA study. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, d’Arminio Monforte A, Fox Z and Lundgren JD for the EuroSIDA study group.
AIDS 2002 Aug16;16(12):1663-1671 abstract

9 Safe interruption of maintenance therapy against prior infection with four common HIV-associated opportunistic pathogens during antiretroviral therapy. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit F, Ledergerber B, Lundgren JD, Furrer H, for seven European HIV cohorts. Ann Intern Med. 2002 Aug 20;137(4):239-50 abstract

10 Development of a Rapid Real-Time PCR Assay for Quantitation of Pneumocystis carinii f. sp. Carinii. Larsen HH, Kovacs JA, Stock F,Vestereng VH, Lundgren B, Fischer SH, and Gill VJ. J Clin Microbiol. 2002 Aug;40(8):2989-93 abstract

11 Analysis of virological efficacy in trials of antiretroviral regimens: Drawbacks of not including viral load measurements after premature discontinuation of therapy.  Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron Jr. JJ, Phillips AN and Lundgren JD. Antivir Ther. 2002 Dec;7(4)271-81 abstract

12 Regional and Temporal changes in AIDS in Europe before HAART.Blaxhult A, Fox Z, Colebunders R, Francioli P, Ben-Ishai Z,Fätkenheuer G, Parkin JM, Vanhems P, Phillips AN and Kirk O for the EuroSIDA Study Group. Epidemiol Infect. 2002 Dec;129(3):565-77 abstract

13 Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia – a case-control study. Helweg-Larsen J, Jensen JS, Dohn G, Benfield TL and Lundgren B. BMC Infect Dis. 2002 Nov 25;2(1):28 abstract

14 Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Davis F, Sostagliola D, D’Arminio Monforte A, de Wolf F,Reiss P, Lundgren JD, Jusitce AC, Staszewski S, Leport C, Hogg RS, Sabin CA,Gill MJ, Salzberger B, Sterne JA and the ART cohort collaboration. Lancet. 2002Jul 13;360(9327):119-29 abstract

15 YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Østergaard C, Johansen JS, Benfield T, Price PA and Lundgren JD. Clin Diagn Lab Immunol. 2002 May;9(3):598-604 abstract

16 Changes over calendartime in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Wlaker SA, Beral V, Coutinho R, Del Amo J, Gill N, Lee C,Meyer L, Tyrer F, Dabis F, Thiebaut R, Lawson-Aye S, Boufassa F, Hamouda O,Fischer K, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, Brettle R, DelRomero J, Prins M, van Benthem B, Kirk O, Pederson C, Hernandez Aguado I,Prez-Hoyos S, Eskild A, Bruun JN, Sannes M, Sabin C, Lee C, Johnson AM,Phillips AN, Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J,Ashton L, Vizzard J, Muga R, Day NE, De Angelis D for the CASCADE collaboration.
Int J Epidemiol. 2002 Oct;31(5):951-8 abstract

17 Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. Larsen HH, Masur H, Kovacs JA,Gill VJ, Silcott VA, Kogulan P, Maenza J, Smith M, Lucey DR and Fischer SH. J Clin Microbiol. 2002 Feb;40(2):490-4 abstract

18 Pneumocysitis carinii Pneumonia. Helweg-Larsen J, Lundgren JD, and Benfield T Current Treatment Options in Infectiuos Diseases. 2002;4(4):363-375. abstract


1 Independent risk of mechanical ventilation for AIDS-related Pneumocystis carinii pneumonia associated with bronchoalveolar lavage neutrophilia.
Bang D, Emborg J, Elkjaer J, Lundgren JD, and Benfield T Respir Med. 2001;95(8):661-665. abstract

2 Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Benfield TL, Helweg-Larsen J, Bang D, Junge J, and Lundgren JD  Chest. 2001;119(3):844-851. abstract

3 PCR-RFLP analysis of the DHPS gene for the study of resistance of Pneumocystis carinii to sulpha drugs in patients with co-infection PCP/HIV. Costa MC, Helweg-Larsen J, Antunes F, Lundgren B, Diogo J, and Matos O J Eukaryot Microbiol.2001;Suppl(148S-149S). abstract

4 Highly active antiretroviral therapy and coronary heart disease: the need for perspective. Egger M, Junghans C, Friis-Moller N, and Lundgren JD. AIDS. 2001;15Suppl 5(S193-S201). abstract

5 [Diagnosis. Pneumocystis carinii]. Helweg-Larsen J and Lundgren B. Ugeskr Laeger. 2001;163(4):477-478. abstract

6 Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis. Helweg-Larsen J, Lee CH, Jin S, Hsueh JY, Benfield TL, Hansen J, Lundgren JD, and Lundgren B. AIDS. 2001;15(4):451-459. abstract

7 Heterogeneity and compartmentalization of Pneumocystis carinii f. sp. hominis genotypes in autopsy lungs. Helweg-Larsen J, Lundgren B,and Lundgren JD J Clin Microbiol. 2001;39(10):3789-3792. abstract

8 Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles o­n HIV-1 disease progression: An international meta-analysis of individual patient data. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, and O'Brien TR for the International Meta-Analysis of HIV Host Genetics Ann Intern Med. 2001;135(9):782-795. abstract

9 The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. Jensen-Fangel S, Kirk O, Blaxhult A, Gerstoft J, Pedersen C, Black FT, Lundgren JD, and Obel N HIV Clin Trials. 2001;2(2):122-127. abstract

10 Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviraltherapy. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhoj P, and Barton SE for the EuroSIDA Study Group Blood. 2001;98(12):3406-3412. abstract

11 Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, Katzenstein TL, Mathiesen L, and Lundgren JD  HIV Med.2001;2(1):43-51. abstract

12 Penicillin as empirical therapy for patients hospitalised with community acquired pneumonia at a Danish hospital. Kirk O, Glenthoj J, Dragsted UB, Helweg-Larsen J, Aru TM, Benfield TL, Jensen K, Vestbo J, and Lundgren JD Dan Med Bull.2001;48(2):84-88. abstract

13 Clinical outcome among HIV-infected patients starting saquinavir hard gel compared toritonavir or indinavir. Kirk O, Mocroft A., Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD and the EuroSIDA Study Group AIDS.2001;15(8):999-1008. abstract

14 Adverse effect of the CCR5 promoter -2459A allele o­n HIV-1 disease progression. Knudsen TB, Kristiansen TB, Katzenstein TL, and Eugen-Olsen J J Med Virol.2001;65(3):441-444. abstract

15 A new multiplex PCR strategy for the simultaneous determination of fourgenetic polymorphisms affecting HIV-1 disease progression. Kristiansen TB, Knudsen TB, Ohlendorff S, and Eugen-Olsen J J Immunol Methods. 2001;252(1-2):147-151. abstract

16 Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, and Lundgren JD for eight European Study Groups N Engl J Med.2001;344(3):168-174. abstract

17 When to start and stop? Lundgren JD HIV Med.2001;2(4):229-230. abstract

18 [Heterosexual transmission of HIV in Denmark in2001. A real risk or a negligible problem?]. Lundgren JD Ugeskr Laeger.2001;163(42):5811. abstract

19 The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, and Lundgren JD o­n behalf of the EuroSIDA Study Group AIDS.2001;15(2):201-209. abstract

20 HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, and Ledergerber B for the Swiss HIV Cohort, the Frankfurt HIV Clinic Cohort and the EuroSIDA Study Group. JAMA.2001;286(20):2560-2567. abstract

21 Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD o­n behalf of the EuroSIDA Study Group AIDS.2001;15(18):2385-2395. abstract

22 Influence of age o­n CD4 cell recovery in human immunodeficiency virus- infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, Vetter N, Bruun JN, Johnson M, and Lundgren JD for the EuroSIDA Study Group J Infect Dis.2001;183(8):1290-1294.abstract

23 An open-label randomized trial to evaluate different therapeutic strategies for combination therapy in HIV-1 infection: Design, rationale and methods of the INITIO trial. The INITIO co-ordination committee, Babiker AG, Darbyshire J, Cooper DA, Hooker MH, Withnall R and Yeni P. Control Clin Trials. 2001;22(2):160-175 abstract


1 Regional differences in presentation of AIDS in Europe.
Blaxhult A, Kirk O, Pedersen C, Dietrich M, Barton SE, Gatell JM, Mulcahy F, Hirschel B, Mocroft A, and Lundgren JD for the AIDS in Europe Study Group Epidemiol Infect. 2000;125(1):143-151. abstract

2 Prevalence and prognostic significance of infection with TT virus in patients infected with human immunodeficiency virus. Christensen JK, Eugen-Olsen J, Sørensen M, Ullum H, Gjedde SB, Pedersen BK, Nielsen JO, and Krogsgaard K J Infect Dis.2000;181(5):1796-1799. abstract

3 Relapse of multiresistant Salmonella typhi after combined therapy with ciprofloxacin and ceftriaxone. Dragsted UB and Pedersen P
Clin Microbiol Infect. 2000;6(3):167-168. abstract

4 Aldesleukin Chiron Therapeutics. Dragsted UB and Lundgren JD. Curr Opin Investig Drugs. 2000;2(3):323-331

5 [Treatment of HIV infections with antiretroviral drugs and recombinant interleukin-2]. Dragsted UB, Afzelius P, Nielsen SD, and Lundgren JD  Ugeskr Laeger. 2000;162(42):5614-5618. abstract

6 Effect of the serotonin receptor agonist, buspirone, o­n immune function in HIV-infected individuals: a six-month randomized, double-blind, placebo-controlled trial. Eugen-Olsen J, Benfield T, Axen TE, Parner J, Iversen J, Pedersen C, and Nielsen JO HIV Clin Trials. 2000;1(1):20-26. abstract

7 Human immunodeficiency virus-associated malignant lymphoma in eastern Denmark diagnosed from 1990-1996: clinical features, histopathology, and association with Epstein-Barr virus and human herpesvirus-8. Hansen PB, Penkowa M, Kirk O, Skinhoj P, Pedersen C, Lisse I, Kiss K, Zhou X, and Hamilton-Dutoit SJ Eur J Haematol. 2000;64(6):368-375. abstract

8 Rapid detection of dihydropteroate polymorphism in AIDS-related Pneumocystis carinii pneumonia by restriction fragment length polymorphism. Helweg-Larsen J, Eugen-Olsen J, and Lundgren B. Scand J Infect Dis. 2000;32(5):481-483. abstract

9 The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. Katzenstein TL, Kirk O, Pedersen C, Lundgren JD, Nielsen H, Obel N, Nielsen C, Mathiesen LR, and Gerstoft J J Infect Dis. 2000;182(3):744-750. abstract

10 Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, Barton SE, Sudre P, and Phillips AN and Lundgren JD for the EuroSIDA Study Group Am J Respir Crit Care Med. 2000;162(3 Pt 1):865-872. abstract

11 [The Society of Theoretical and Applied Therapy.´The medal of honour for the year of 2000]. Lundgren JD
Ugeskr Laeger. 2000;162(47):6424- abstract

12 [Atovaquone/proguanil. Prophylaxis and treatment of malaria]. Lundgren JD and Dragsted UB Ugeskr Laeger. 2000;162(31):4177-4181. abstract

13 AIDS across Europe, 1994-98: the EuroSIDA study. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, and Lundgren JD for the EuroSIDA Study Group Lancet. 2000;356(9226):291-296. abstract

14 Virological failure among patients o­n HAART from across Europe: results from the EuroSIDA study. Mocroft A, Miller V, Chiesi A, Blaxhult A, Katlama C, Clotet B, Barton S, and Lundgren JD Antivir Ther. 2000;5(2):107-112. abstract

15 Use of medical chemoprophylaxis and antimosquito precautions in Danish malaria patients and their traveling companions. Mølle I, Christensen KL, Hansen PS, Dragsted UB, Aarup M, and Buhl MR J Travel Med. 2000;7(5):253-258. abstract

16 Treatment with a monocolonal antibody to IL-8 attenuates the pleocytosis in experimental pneumococcal meningitis in rabbits when given intravenously, but not intracisternally. Østergaard C, Yieng-Kow RV, Larsen CG, Mukaida N, Matsushima K, Benfield T, Frimodt-Moller N, Espersen F, Kharazmi A, and Lundgren JD Clin Exp Immunol. 2000;122(2):207-211. abstract

17 Inhibition of leukocyte entry into the brain by the selectin blocker fucoidin decreases interleukin-1 (IL-1) levels but increases IL-8 levels in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Østergaard C, Yieng-Kow RV, Benfield T, Frimodt-Moller N, Espersen F, and Lundgren JD  Infect Immun. 2000;68(6):3153-3157. abstract

18 Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, and Clotet B for the EuroSIDA Study Group Arch Intern Med. 2000;160(8):1123-1132. abstract

19 Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Sidenius N, Sier CFM, Ullum H, Pedersen BK, Lepri AC, Blasi F, and Eugen-Olsen J
Blood. 2000;96(13):4091-4095. abstract